The first neutralizing mAbs to FGF2 were described in 1989–1991, but the role of FGF2 in bone diseases had long been unknown, and the discrepant reports were made on the role of FGF2 in bone disorders in 1998–2002 as described above. Here, FGF2 is linked to bone disorder.